MCID: TTN003
MIFTS: 64

Tetanus

Categories: Rare diseases, Neuronal diseases, Infectious diseases

Aliases & Classifications for Tetanus

MalaCards integrated aliases for Tetanus:

Name: Tetanus 12 76 53 59 55 43 3 3 44 15 73
Lockjaw 53 3
Infection Due to Clostridium Tetani 12
Clostridial Tetanus 12

Characteristics:

Orphanet epidemiological data:

59
tetanus
Prevalence: <1/1000000 (France),<1/1000000 (Europe);

Classifications:



External Ids:

Disease Ontology 12 DOID:11338
ICD10 33 A35
ICD9CM 35 037
MeSH 44 D013742
NCIt 50 C85185
Orphanet 59 ORPHA3299
UMLS via Orphanet 74 C0039614
ICD10 via Orphanet 34 A33 A34 A35
MESH via Orphanet 45 D013742
UMLS 73 C0039614

Summaries for Tetanus

MedlinePlus : 43 Tetanus is a serious illness caused by Clostridium bacteria. The bacteria live in soil, saliva, dust, and manure. The bacteria can enter the body through a deep cut, like those you might get from stepping on a nail, or through a burn. The infection causes painful tightening of the muscles, usually all over the body. It can lead to "locking" of the jaw. This makes it impossible to open your mouth or swallow. Tetanus is a medical emergency. You need to get treatment in a hospital. A vaccine can prevent tetanus. It is given as a part of routine childhood immunization. Adults should get a tetanus shot, or booster, every 10 years. If you get a bad cut or burn, see your doctor - you may need a booster. Immediate and proper wound care can prevent tetanus infection.

MalaCards based summary : Tetanus, also known as lockjaw, is related to diphtheria and poliomyelitis, and has symptoms including fever and pruritus. An important gene associated with Tetanus is VAMP7 (Vesicle Associated Membrane Protein 7), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Iron and Natalizumab have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and brain, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A primary bacterial infectious disease that results in prolonged contraction of skeletal muscle fibers, has material basis in Clostridium tetani, which produces tetanospasmin, a neurotoxin, which is carried to the brain and spinal cord, where it binds irreversibly to receptors inhibiting neurotransmission. Damaged upper motor neurons cannot control reflex responses to afferent sensory stimuli.

CDC : 3 Tetanus is an infection caused by bacteria called Clostridium tetani. When the bacteria invade the body, they produce a poison (toxin) that causes painful muscle contractions. Another name for tetanus is “lockjaw”. It often causes a person’s neck and jaw muscles to lock, making it hard to open the mouth or swallow. CDC recommends vaccines for infants, children, teens, and adults to prevent tetanus.

Wikipedia : 76 Tetanus, also known as lockjaw, is an infection characterized by muscle spasms. In the most common type,... more...

Related Diseases for Tetanus

Diseases related to Tetanus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 380)
# Related Disease Score Top Affiliating Genes
1 diphtheria 32.3 IL13 IL2 IL2RA
2 poliomyelitis 31.6 IFNG IL10 IL4
3 mumps 31.1 CD40LG IFNG IL2
4 measles 31.0 CD40LG IFNG IL2 IL4
5 rubella 31.0 CD40LG IL10 IL4
6 lepromatous leprosy 30.9 IFNG IL10 IL2
7 reactive arthritis 30.6 CD79A IFNG IL10
8 hematopoietic stem cell transplantation 30.5 IFNG IL10 IL2
9 herpes zoster 30.4 IFNG IL10 IL2
10 erythema multiforme 30.4 CD79A IFNG IL2
11 meningitis 30.2 CD40LG IFNG IL10
12 shigellosis 30.1 CD79A IL10 LTA
13 myasthenia gravis 30.1 IFNG IL10 IL2 IL4
14 wells syndrome 30.0 IL2 IL2RA IL5
15 onchocerciasis 30.0 IL13 IL2 IL4 IL5
16 milk allergy 30.0 CD79A IL10 IL4 IL5
17 cervicitis 29.9 CD79A IL2 IL2RA
18 pneumonia 29.8 CD40LG IL10 IL13 IL5
19 rheumatic disease 29.7 CD40LG IFNG IL10 IL2RA
20 psoriasis 29.4 IFNG IL10 IL13 IL2 IL4 LTA
21 combined immunodeficiency, x-linked 29.1 CD40LG CD79A IL2 IL2RA IL4
22 malaria 28.4 CD40LG IFNG IL10 IL13 IL2 IL4
23 rheumatoid arthritis 28.3 CD40LG CD79A IFNG IL10 IL2 IL2RA
24 systemic lupus erythematosus 28.1 CD40LG CD79A IFNG IL10 IL2 IL2RA
25 schistosomiasis 28.0 CD40LG CD79A IFNG IL10 IL13 IL2
26 multiple sclerosis 27.8 CCR7 IFNG IL10 IL2 IL2RA IL4
27 asthma 27.7 CD40LG CD79A IFNG IL10 IL13 IL2RA
28 tetanus neonatorum 12.5
29 crisponi/cold-induced sweating syndrome 1 11.2
30 mycoplasmal pneumonia 11.0 IFNG IL4
31 juvenile spondyloarthropathy 11.0 IL2 LTA
32 variola major 10.9 IFNG IL2
33 tropical endomyocardial fibrosis 10.9 IL10 IL4
34 ross river fever 10.9 CD40LG IL10
35 neuroschistosomiasis 10.9 CD79A IFNG
36 immunodeficiency 25 10.9
37 specific antibody deficiency 10.9
38 selective igg deficiency disease 10.9 CD40LG CD79A
39 eosinophilic fasciitis 10.9 IFNG IL5
40 c1q nephropathy 10.9 CD40LG CD79A
41 virus associated hemophagocytic syndrome 10.9 IL2 IL4
42 meningovascular neurosyphilis 10.8 CD40LG CD79A
43 alpha chain disease 10.8 CD40LG CD79A
44 brill-zinsser disease 10.8 CD40LG CD79A
45 exudative glomerulonephritis 10.8 CD40LG CD79A
46 cork-handlers' disease 10.8 CD40LG CD79A
47 salpingo-oophoritis 10.8 CD40LG CD79A
48 autoimmune myocarditis 10.8 IFNG IL2
49 chronic active epstein-barr virus infection 10.8 IFNG IL10 IL2
50 baylisascariasis 10.8 IFNG IL10 IL4

Graphical network of the top 20 diseases related to Tetanus:



Diseases related to Tetanus

Symptoms & Phenotypes for Tetanus

UMLS symptoms related to Tetanus:


fever, pruritus

GenomeRNAi Phenotypes related to Tetanus according to GeneCards Suite gene sharing:

26 (show all 46)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.2 IL10 CCR7
2 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.2 IL13
3 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.2 IL10
4 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.2 CCR7
5 Increased shRNA abundance (Z-score > 2) GR00366-A-125 10.2 IL10
6 Increased shRNA abundance (Z-score > 2) GR00366-A-128 10.2 IL10 CCR7 IL13 VAMP7
7 Increased shRNA abundance (Z-score > 2) GR00366-A-130 10.2 IL13
8 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.2 IL10
9 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.2 VAMP7
10 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.2 IL10
11 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.2 VAMP7
12 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.2 IL10
13 Increased shRNA abundance (Z-score > 2) GR00366-A-172 10.2 CCR7
14 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.2 IL10 CCR7
15 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.2 IL13
16 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.2 IL10
17 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.2 IL10
18 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.2 CCR7
19 Increased shRNA abundance (Z-score > 2) GR00366-A-24 10.2 VAMP7
20 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.2 IL10
21 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.2 VAMP7
22 Increased shRNA abundance (Z-score > 2) GR00366-A-39 10.2 IL13
23 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.2 VAMP7
24 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.2 IL10
25 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.2 VAMP7
26 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.2 IL10
27 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.2 VAMP7
28 Increased shRNA abundance (Z-score > 2) GR00366-A-80 10.2 IL10
29 Increased shRNA abundance (Z-score > 2) GR00366-A-82 10.2 IL10
30 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.2 IL10
31 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 10.13 IL2RA
32 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 10.13 IL2RA
33 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 10.13 NSF IL10
34 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 10.13 IL2RA NSF IL10 VAMP7
35 Decreased shRNA abundance (Z-score < -2) GR00366-A-181 10.13 IL2RA
36 Decreased shRNA abundance (Z-score < -2) GR00366-A-191 10.13 VAMP7
37 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 10.13 VAMP7
38 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 10.13 IL2RA
39 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.13 NSF
40 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 10.13 IL2RA IL10
41 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.13 IL10
42 Decreased shRNA abundance (Z-score < -2) GR00366-A-65 10.13 IL10
43 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 10.13 IL10
44 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 10.13 NSF
45 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 IL10 IL2 IL2RA LTA STX3 CD40LG
46 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 IL10 IL2 IL2RA LTA STX3 CD27

MGI Mouse Phenotypes related to Tetanus:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.31 CD40LG IL13 CD79A IFNG IL2 CCR7
2 hematopoietic system MP:0005397 10.3 CD40LG IL13 CD79A IFNG IL2 CCR7
3 immune system MP:0005387 10.28 IL13 CD79A IFNG IL2 CCR7 IL10
4 endocrine/exocrine gland MP:0005379 10.22 CD40LG IL13 IFNG IL2 CCR7 IL10
5 mortality/aging MP:0010768 10.13 IL10 CD40LG IL13 IFNG IL2RA NSF
6 digestive/alimentary MP:0005381 10.1 IL10 IL13 IFNG CCR7 IL2RA IL4
7 nervous system MP:0003631 10 IL10 CD40LG CD79A IFNG CCR7 SNAP25
8 liver/biliary system MP:0005370 9.97 IL10 CD79A IFNG IL4 SNAP25 IL5
9 no phenotypic analysis MP:0003012 9.81 CD79A IL13 IFNG CCR7 IL10 SNAP23
10 respiratory system MP:0005388 9.61 IL13 IFNG IL10 IL4 SNAP25 IL5
11 vision/eye MP:0005391 9.28 IL10 IFNG CCR7 IL2RA NSF IL4

Drugs & Therapeutics for Tetanus

Drugs for Tetanus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 317)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iron Approved Phase 4,Phase 3,Phase 2,Not Applicable 7439-89-6 23925
2
Natalizumab Approved, Investigational Phase 4 189261-10-7
3
Benzocaine Approved, Investigational Phase 4,Not Applicable 1994-09-7, 94-09-7 2337
4
Remifentanil Approved Phase 4,Not Applicable 132875-61-7 60815
5
Methotrexate Approved Phase 4,Phase 3,Phase 2 1959-05-2, 59-05-2 126941
6
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 60-00-4, 62-33-9 6049
7
Pentetic acid Approved Phase 4,Phase 3,Phase 2 67-43-6
8
rituximab Approved Phase 4,Phase 3,Phase 2,Not Applicable 174722-31-7 10201696
9
Adalimumab Approved Phase 4 331731-18-1 16219006
10
Etanercept Approved, Investigational Phase 4 185243-69-0
11
Desflurane Approved Phase 4 57041-67-5 42113
12
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
13
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
14
Rocuronium Approved Phase 4,Not Applicable 119302-91-9, 143558-00-3 441290
15
Sevoflurane Approved, Vet_approved Phase 4,Not Applicable 28523-86-6 5206
16
Acetaminophen Approved Phase 4,Phase 3 103-90-2 1983
17
Ibuprofen Approved Phase 4,Phase 2 15687-27-1 3672
18
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
19
Abatacept Approved Phase 4,Phase 2,Phase 1 332348-12-6 10237
20
Efavirenz Approved, Investigational Phase 4,Not Applicable 154598-52-4 64139
21
Ritonavir Approved, Investigational Phase 4,Not Applicable 155213-67-5 392622
22
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
23
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
24
Lopinavir Approved Phase 4 192725-17-0 92727
25
Maraviroc Approved, Investigational Phase 4 376348-65-1 3002977
26
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 59-30-3 6037
27
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 58-05-9 143 6006
28 tannic acid Approved, Nutraceutical Phase 4,Not Applicable
29
BCG vaccine Investigational Phase 4,Phase 2
30 Vaccines Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
31 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Antacids Phase 4,Phase 3,Phase 2,Phase 1
34 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2,Phase 1
35 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Central Nervous System Depressants Phase 4,Phase 1,Not Applicable
39 Antidotes Phase 4,Phase 3,Phase 2
40 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Antirheumatic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
42 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Vitamin B Complex Phase 4,Phase 3,Phase 2,Not Applicable
46 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1
47 Anti-Bacterial Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
48 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
49 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Antitubercular Agents Phase 4,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 666)
# Name Status NCT ID Phase Drugs
1 Vaccination Against Pertussis, Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis Unknown status NCT01301703 Phase 4
2 An Immunogenicity and Safety Study of Tetanus, Diphtheria and Acellular Pertussis Vaccine Booster Unknown status NCT00870350 Phase 4
3 The Safety and Immunogenicity of Acellular Pertussis Vaccine in Bone Marrow Transplant Recipients Unknown status NCT00336115 Phase 4
4 Safety, Long Term Immunogenicity and Lot Consistency Study of Liquid Pentavalent Combination Vaccine Unknown status NCT00877357 Phase 4
5 Diphtheria, Tetanus, Poliomyelitis -Pertussis-Hib Immunisation in Preterm-born Neonates Unknown status NCT02179996 Phase 4
6 Pertussis (Tdap) Vaccination in Pregnancy Unknown status NCT01698346 Phase 4
7 Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine Compared With U.S. Manufactured Td Completed NCT00601835 Phase 4
8 Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine Completed NCT03552445 Phase 4
9 Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous Dose Completed NCT00712959 Phase 4
10 Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio Vaccine Completed NCT00514059 Phase 4 Boostrix polio
11 Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060) Completed NCT01926015 Phase 4
12 Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents Completed NCT01629589 Phase 4
13 Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine Completed NCT00347958 Phase 4
14 Study of Adacel® Vaccine Administered to Persons 10 Years of Age Completed NCT01311557 Phase 4
15 A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Older Completed NCT00457249 Phase 4
16 Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose Completed NCT01439165 Phase 4
17 Phase IV Interchangeability Study of a Liquid Pentavalent Combination Vaccine Completed NCT00674908 Phase 4
18 Evaluation of Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) Vaccine Squarekids™ Co-administered With GSK Biologicals' Human Rotavirus (HRV) Vaccine Rotarix™ (GSK444563) in Healthy Infants Completed NCT02907216 Phase 4
19 Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX® Completed NCT00319553 Phase 4
20 US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease Completed NCT00282295 Phase 4
21 Regulatory Post-Marketing Surveillance Study for TETRAXIM™ Completed NCT01437423 Phase 4
22 Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine Completed NCT00304265 Phase 4
23 Post Marketing Surveillance for ADACEL™ in South Korea Completed NCT01137435 Phase 4
24 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents Completed NCT01424644 Phase 4
25 A Trial Evaluating a 7-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants. Completed NCT01250756 Phase 4
26 Tdap Vaccine in Post-Partum Women Completed NCT01711645 Phase 4
27 Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™ Completed NCT00802867 Phase 4
28 Randomized Study of Not Giving Diphteria-tetanus-pertussis Vaccination With or After Measles Vaccination Completed NCT00244673 Phase 4
29 Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE Completed NCT01546909 Phase 4
30 Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age Completed NCT01659996 Phase 4
31 The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis Completed NCT00536120 Phase 4
32 Safety and Immunogenicity Study of a Liquid Pentavalent Combination Vaccine Completed NCT00617812 Phase 4
33 Interest of a Tetanus Test at a Fixed Remifentanil Concentration Before Laryngoscopy and Skin Incision Completed NCT02884310 Phase 4 Remifentanil adapted to SPI;Remifentanil fixed
34 Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood Vaccination Completed NCT01357720 Phase 4
35 Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination. Completed NCT00610168 Phase 4
36 Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine Completed NCT00777257 Phase 4
37 Concomitant Use of Hepatitis A Vaccine, Inactivated With Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Given to Healthy Children 15 Months of Age (V251-068) Completed NCT00289913 Phase 4
38 Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Completed NCT02422264 Phase 4 Prevnar13
39 Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines Completed NCT00254917 Phase 4
40 Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand Completed NCT00255021 Phase 4
41 Evaluating the Effect of Anakinra (r-metHuIL-1ra) on Vaccine AntibodyResponse in Subjects With Rheumatoid Arthritis (RA) Completed NCT00111410 Phase 4 Anakinra (r-metHuIL-1ra)
42 Tropical Influenza Control Strategies for the Elderly Completed NCT02655874 Phase 4
43 Induction and Expansion of T Cell Repertoire Using Growth Hormone and Vaccination in HIV-1 Infected Patients Completed NCT00287677 Phase 4 HAART
44 Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of Age Completed NCT01031303 Phase 4
45 Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults Completed NCT01323959 Phase 4
46 Evaluation of Boostrix™10 Years After Previous Booster Vaccination Completed NCT01147900 Phase 4
47 Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination Completed NCT00548171 Phase 4
48 Immunology of Non-specific Effects of Vaccine Completed NCT00168545 Phase 4
49 A Study of the Effects of RoActemra/Actemra on Vaccination in Patients With Rheumatoid Arthritis on Background Methotrexate (VISARA) Completed NCT01163747 Phase 4 methotrexate
50 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Pregnant Women Completed NCT02377349 Phase 4 Saline placebo

Search NIH Clinical Center for Tetanus

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: tetanus

Genetic Tests for Tetanus

Anatomical Context for Tetanus

MalaCards organs/tissues related to Tetanus:

41
Testes, T Cells, Brain, Bone, Spinal Cord, B Cells, Heart

Publications for Tetanus

Articles related to Tetanus:

(show top 50) (show all 1125)
# Title Authors Year
1
Intravascular Ketamine Increases Theta-Burst but Not High Frequency Tetanus Induced LTP at CA3-CA1 Synapses Within Three Hours and Devoid of an Increase in Spine Density. ( 29899695 )
2018
2
Immunization rates of pneumococcal, influenza and tetanus vaccines and knowledge and attitudes of adult patients who receive inpatient treatment at hospital: Point prevalence study. ( 29913102 )
2018
3
Myocarditis following diphtheria, whole-cell pertussis, and tetanus toxoid vaccination in a young infant. ( 29922028 )
2018
4
A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults. ( 29172945 )
2018
5
Safety of repeated doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine in adults and adolescents. ( 29862604 )
2018
6
Pre-vaccine plasma levels of soluble inflammatory indices negatively predict responses to HAV, HBV, and tetanus vaccines in HCV and HIV infection. ( 29254840 )
2018
7
Repeated vaccination with tetanus toxoid of plasma donors with pre-existing specific IgE transiently elevates tetanus-specific IgE but does not induce allergic symptoms. ( 29383792 )
2018
8
Effectiveness of Prenatal Tetanus, Diphtheria, Acellular Pertussis Vaccination in the Prevention of Infant Pertussis in the U.S. ( 29910115 )
2018
9
Cyclic OmpC peptidic epitope conjugated to tetanus toxoid as a potential vaccine candidate against shigellosis. ( 29960802 )
2018
10
Randomized Controlled Trial of the Safety and Immunogenicity of Revaccination With Tetanus-Diphtheria-Acellular Pertussis Vaccine (Tdap) in Adults 10 Years After a Previous Dose. ( 29438562 )
2018
11
A quality improvement initiative to increase Tdap (tetanus, diphtheria, acellular pertussis) vaccination coverage among direct health care providers at a children's hospital. ( 29217370 )
2018
12
Pharmacists' Attitudes and Practices Regarding Tetanus, Diphtheria and Pertussis (Tdap) Vaccination in Pregnancy and Surrounding Newborns. ( 29693570 )
2018
13
Tetanus toxin fragments and Bcl-2 fusion proteins: cytoprotection and retrograde axonal migration. ( 29890980 )
2018
14
A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial. ( 29066131 )
2018
15
The novel early use of dexmedetomidine in the management of tetanus. ( 29940468 )
2018
16
Pneumococcal Immune Response in Infants Whose Mothers Received Tetanus, Diphtheria and Acellular Pertussis Vaccination During Pregnancy: ERRATUM. ( 29652740 )
2018
17
Patient attitudes toward influenza and tetanus, diphtheria and acellular pertussis vaccination in pregnancy. ( 29907484 )
2018
18
A rare case of type 1 leprosy reactions following tetanus infection in a borderline tuberculoid leprosy patient and a literature review. ( 29908564 )
2018
19
Relationship between patient copayments in Medicare Part D and vaccination claim status for herpes zoster and tetanus-diphtheria-acellular pertussis. ( 29231748 )
2018
20
Immunization of preterms with hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: The position of the Italian Pediatric Society. ( 29880242 )
2018
21
Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults: A phase III, randomized study. ( 29960800 )
2018
22
Sero-efficacy of Vi-polysaccharide tetanus-toxoid typhoid conjugate vaccine (Typbar-TCV). ( 29351594 )
2018
23
Lichen planus following tetanus-diphtheria-acellular pertussis vaccination: A case report and review of the literature. ( 29326823 )
2018
24
Functional and proteomic comparison of different techniques to produce equine anti-tetanus immunoglobulin F(ab')2 fragments. ( 29883887 )
2018
25
Determinants and perceptions of the utilization of tetanus toxoid immunization among reproductive-age women in Dukem Town, Eastern Ethiopia: a community-based cross-sectional study. ( 29950171 )
2018
26
Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP). ( 29702631 )
2018
27
Immunization of preterm infants with GSK's hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: A review of safety and immunogenicity. ( 29336924 )
2018
28
A Pilot Study to Assess Safety and Feasibility of Intrathecal Immunoglobulin for the Treatment of Adults with Tetanus. ( 29916342 )
2018
29
Prognostic factors for generalized tetanus in adults: A retrospective study in a Chinese hospital. ( 29891121 )
2018
30
The role of timely initiation of antenatal care on protective dose tetanus toxoid immunization: the case of northern Ethiopia post natal mothers. ( 29907139 )
2018
31
Tetanus in a partially immunized child. ( 29866490 )
2018
32
Synthesis of peptide based epsilon toxin vaccine by covalent anchoring to tetanus toxoid. ( 29920342 )
2018
33
Safety Surveillance of Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) Vaccines. ( 29866795 )
2018
34
Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10A years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study. ( 29630439 )
2018
35
Immunogenicity and safety of a novel tetanus toxoid-conjugated anti-gastrin vaccine in BALB/c mice. ( 29306507 )
2018
36
Diphtheria, pertussis, and tetanus: evidence-based management of pediatric patients in the emergency department ( 28749121 )
2017
37
Tetanus Toxoid carrier protein induced T-helper cell responses upon vaccination of middle-aged adults. ( 28882444 )
2017
38
High Conservation of Tetanus and Botulinum Neurotoxins Cleavage Sites on Human SNARE Proteins Suggests That These Pathogens Exerted Little or No Evolutionary Pressure on Humans. ( 29257047 )
2017
39
Functionally Convergent B Cell Receptor Sequences in Transgenic Rats Expressing a Human B Cell Repertoire in Response to Tetanus Toxoid and Measles Antigens. ( 29312330 )
2017
40
Definition of Human Epitopes Recognized in Tetanus Toxoid and Development of an Assay Strategy to Detect Ex Vivo Tetanus CD4+ T Cell Responses. ( 28081174 )
2017
41
Soil transmitted helminth infections are not associated with compromised antibody responses to previously administered measles and tetanus vaccines among HIV-1 infected, ART naA^ve Kenyan adults. ( 28924616 )
2017
42
Augmentation of humoral and cellular immunity in response to Tetanus and Diphtheria toxoids by supercritical carbon dioxide extracts of Hippophae rhamnoides L. leaves. ( 28092864 )
2017
43
Tetanus-induced Trismus: Improvement on a Daily Basis. ( 28924130 )
2017
44
Long-term outcome in survivors of neonatal tetanus following specialist intensive care in Vietnam. ( 28946862 )
2017
45
Immunoadjuvant potential of cross-linked dextran microspheres mixed with chitosan nanospheres encapsulated with tetanus toxoid. ( 27927058 )
2017
46
Committee Opinion No. 718: Update on Immunization and Pregnancy: Tetanus, Diphtheria, and Pertussis Vaccination. ( 28832489 )
2017
47
Neuroprotective effects of C-terminal domain of tetanus toxin on rat brain against motorneuron damages after experimental spinal cord injury. ( 28767631 )
2017
48
Clinical Profile and Outcome of Pediatrics Tetanus: The Experience of a Tertiary Hospital in Ethiopia. ( 29217961 )
2017
49
Demand- and supply-side determinants of diphtheria-pertussis-tetanus nonvaccination and dropout in rural India. ( 28081971 )
2017
50
Negative Correlation between Circulating CD4(+)FOXP3(+)CD127(-) Regulatory T Cells and Subsequent Antibody Responses to Infant Measles Vaccine but Not Diphtheria-Tetanus-Pertussis Vaccine Implies a Regulatory Role. ( 28855899 )
2017

Variations for Tetanus

Expression for Tetanus

Search GEO for disease gene expression data for Tetanus.

Pathways for Tetanus

Pathways related to Tetanus according to GeneCards Suite gene sharing:

(show all 48)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.04 CD27 CD40LG CD79A IFNG IL10 IL13
2
Show member pathways
13.87 CCR7 CD27 CD40LG IL10 IL13 IL2
3
Show member pathways
13.69 CCR7 CD27 CD40LG IFNG IL10 IL13
4
Show member pathways
13.5 IFNG IL10 IL13 IL2 IL2RA IL4
5
Show member pathways
13.44 CCR7 CD27 CD40LG IL10 IL13 IL2
6
Show member pathways
13.35 CD27 CD40LG IFNG IL10 IL13 IL2
7
Show member pathways
13.31 CCR7 CD27 CD40LG IL10 IL13 IL2
8
Show member pathways
12.87 CD40LG IFNG IL10 IL13 IL2 IL2RA
9 12.84 IFNG IL13 IL2 IL2RA IL4 IL5
10
Show member pathways
12.79 IFNG IL13 IL2 IL2RA IL4 LTA
11
Show member pathways
12.78 CD79A IFNG IL2 IL2RA IL4
12
Show member pathways
12.63 IFNG IL10 IL13 IL2 IL2RA IL4
13 12.59 CD40LG CD79A IFNG IL10 IL2 IL2RA
14
Show member pathways
12.49 CD40LG IFNG IL10 IL2 IL4 IL5
15
Show member pathways
12.48 IFNG IL10 IL13 IL2 IL2RA IL4
16
Show member pathways
12.45 NSF SNAP23 SNAP25 VAMP2 VAMP7
17
Show member pathways
12.42 IL13 IL2 IL2RA IL5
18
Show member pathways
12.32 IFNG IL13 IL4 IL5
19
Show member pathways
12.25 IFNG IL10 IL2 LTA
20
Show member pathways
12.25 CD40LG IFNG IL10 IL4
21 12.17 IL10 IL13 SNAP25 VAMP2
22
Show member pathways
12.14 IFNG IL10 IL13 IL2 IL2RA IL4
23
Show member pathways
12.04 IL13 IL2 IL2RA IL5
24
Show member pathways
12 NSF SNAP25 STX3 VAMP2
25
Show member pathways
11.99 IFNG IL2 IL2RA IL4
26
Show member pathways
11.94 SNAP23 SNAP25 STX3 VAMP2 VAMP3 VAMP7
27 11.92 CCR7 CD79A IFNG IL10 IL2 IL2RA
28 11.9 IFNG IL10 IL2 IL2RA
29 11.87 IFNG IL13 IL2 IL4 IL5
30
Show member pathways
11.76 CD40LG IFNG IL2 IL2RA IL4 IL5
31 11.74 IFNG IL10 IL2
32
Show member pathways
11.74 IL2 IL2RA IL4 LTA
33 11.72 CD40LG IL10 IL4 IL5 LTA
34 11.66 IL13 IL4 IL5
35
Show member pathways
11.66 CD40LG IFNG IL2
36
Show member pathways
11.64 IFNG IL2 IL2RA
37 11.57 CD27 CD40LG IL10
38 11.54 IL10 IL13 IL4
39 11.53 CD40LG IFNG IL10
40 11.46 IFNG IL10 IL13 IL2 IL2RA IL4
41
Show member pathways
11.42 NSF SNAP25 VAMP2
42 11.4 IFNG IL13 IL4 IL5
43 11.36 CD40LG IFNG IL2 IL2RA IL4 IL5
44 11.36 IFNG IL10 IL13 IL2 IL2RA IL4
45 11.32 IFNG IL13 IL2 IL2RA
46 11.28 IFNG IL10 IL13 IL2 IL4 IL5
47 10.65 SNAP25 VAMP2
48 10.58 IFNG IL10 IL13 IL2 IL4 IL5

GO Terms for Tetanus

Cellular components related to Tetanus according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 intracellular GO:0005622 9.97 CCR7 CD27 CD40LG IFNG IL2 IL2RA
2 synapse GO:0045202 9.96 SNAP23 SNAP25 VAMP2 VAMP3 VAMP7
3 cell surface GO:0009986 9.93 CCR7 CD27 CD40LG IL2RA VAMP3 VAMP7
4 synaptic vesicle GO:0008021 9.71 SNAP25 STX3 VAMP2 VAMP7
5 phagocytic vesicle membrane GO:0030670 9.67 SNAP23 VAMP3 VAMP7
6 clathrin-coated vesicle membrane GO:0030665 9.65 VAMP2 VAMP3 VAMP7
7 neuron projection GO:0043005 9.63 SNAP23 SNAP25 STX3 VAMP2 VAMP3 VAMP7
8 specific granule GO:0042581 9.57 SNAP23 STX3
9 secretory granule GO:0030141 9.56 STX3 VAMP2 VAMP3 VAMP7
10 azurophil granule GO:0042582 9.52 SNAP23 STX3
11 zymogen granule membrane GO:0042589 9.51 STX3 VAMP2
12 synaptobrevin 2-SNAP-25-syntaxin-1a-complexin I complex GO:0070032 9.43 SNAP25 VAMP2
13 external side of plasma membrane GO:0009897 9.43 CCR7 CD27 CD40LG CD79A IL13 IL2RA
14 SNARE complex GO:0031201 9.1 SNAP23 SNAP25 STX3 VAMP2 VAMP3 VAMP7
15 plasma membrane GO:0005886 10.21 CCR7 CD27 CD40LG CD79A IL2RA LTA
16 extracellular region GO:0005576 10.2 CD27 CD40LG IFNG IL10 IL13 IL2
17 extracellular space GO:0005615 10.14 CD40LG IFNG IL10 IL13 IL2 IL4

Biological processes related to Tetanus according to GeneCards Suite gene sharing:

(show all 41)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.98 CCR7 CD27 CD40LG IL10 IL13 IL2RA
2 response to lipopolysaccharide GO:0032496 9.97 CCR7 CD27 IL10 IL13 LTA
3 cytokine-mediated signaling pathway GO:0019221 9.91 IL10 IL13 IL2 IL2RA IL4 IL5
4 B cell differentiation GO:0030183 9.87 CD40LG CD79A IL10 IL4
5 regulation of signaling receptor activity GO:0010469 9.86 CD40LG IFNG IL10 IL13 IL2 IL4
6 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.85 IFNG IL13 IL2
7 positive regulation of T cell proliferation GO:0042102 9.84 CD40LG IL2 IL2RA IL4
8 negative regulation of endothelial cell apoptotic process GO:2000352 9.8 IL10 IL13 IL4
9 long-term synaptic potentiation GO:0060291 9.8 MPP2 SNAP25 STX3 VAMP2
10 B cell proliferation GO:0042100 9.78 CD40LG CD79A IL10
11 positive regulation of B cell proliferation GO:0030890 9.78 IL13 IL2 IL4 IL5
12 positive regulation of interleukin-12 production GO:0032735 9.77 CCR7 CD40LG IFNG
13 post-Golgi vesicle-mediated transport GO:0006892 9.76 SNAP23 VAMP2 VAMP7
14 membrane fusion GO:0061025 9.76 SNAP23 STX3 VAMP2 VAMP3
15 calcium ion regulated exocytosis GO:0017156 9.73 VAMP2 VAMP3 VAMP7
16 regulation of regulatory T cell differentiation GO:0045589 9.72 IFNG IL2 IL2RA
17 Golgi to plasma membrane protein transport GO:0043001 9.71 NSF VAMP2 VAMP3 VAMP7
18 synaptic vesicle fusion to presynaptic active zone membrane GO:0031629 9.7 SNAP23 SNAP25 STX3
19 positive regulation of immunoglobulin secretion GO:0051024 9.69 IL2 IL5 VAMP3
20 positive regulation of receptor recycling GO:0001921 9.68 NSF VAMP3
21 interleukin-2-mediated signaling pathway GO:0038110 9.68 IL2 IL2RA
22 synaptic vesicle priming GO:0016082 9.68 SNAP23 SNAP25
23 positive regulation of isotype switching to IgG isotypes GO:0048304 9.68 IL2 IL4
24 synaptic vesicle docking GO:0016081 9.67 SNAP25 STX3
25 positive regulation of MHC class II biosynthetic process GO:0045348 9.67 IL10 IL4
26 SNARE complex assembly GO:0035493 9.66 VAMP3 VAMP7
27 negative regulation of lymphocyte proliferation GO:0050672 9.66 IL2 IL2RA
28 type 2 immune response GO:0042092 9.65 IL10 IL4
29 natural killer cell degranulation GO:0043320 9.65 VAMP2 VAMP7
30 regulation of isotype switching GO:0045191 9.65 IL10 IL4
31 eosinophil degranulation GO:0043308 9.64 VAMP2 VAMP7
32 exocytic insertion of neurotransmitter receptor to postsynaptic membrane GO:0098967 9.64 SNAP25 STX3
33 mucus secretion GO:0070254 9.63 VAMP2 VAMP3
34 vesicle fusion GO:0006906 9.63 SNAP23 SNAP25 STX3 VAMP2 VAMP3 VAMP7
35 regulation of T cell homeostatic proliferation GO:0046013 9.62 IL2 IL2RA
36 negative regulation of complement-dependent cytotoxicity GO:1903660 9.62 IL13 IL4
37 positive regulation of T cell differentiation GO:0045582 9.62 CD27 IL2 IL2RA IL4
38 regulation of histamine secretion by mast cell GO:1903593 9.61 VAMP2 VAMP3
39 exocytosis GO:0006887 9.5 NSF SNAP23 SNAP25 STX3 VAMP2 VAMP3
40 immune response GO:0006955 9.36 CCR7 CD27 CD40LG IFNG IL10 IL13
41 vesicle-mediated transport GO:0016192 10 NSF STX3 VAMP2 VAMP3 VAMP7

Molecular functions related to Tetanus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 syntaxin binding GO:0019905 9.72 NSF SNAP23 SNAP25 VAMP2 VAMP7
2 growth factor activity GO:0008083 9.71 IL10 IL2 IL4 IL5
3 syntaxin-1 binding GO:0017075 9.56 NSF SNAP25 VAMP2 VAMP3
4 cytokine activity GO:0005125 9.56 CD40LG IFNG IL10 IL13 IL2 IL4
5 SNARE binding GO:0000149 9.55 NSF STX3 VAMP2 VAMP3 VAMP7
6 SNAP receptor activity GO:0005484 9.1 SNAP23 SNAP25 STX3 VAMP2 VAMP3 VAMP7
7 protein binding GO:0005515 10.35 CD27 CD40LG CD79A IFNG IL10 IL13

Sources for Tetanus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....